+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Atrial Fibrillation Market (2021-2026) by Products, Type and Geography - Competitive Analysis, Impact of COVID-19, Ansoff Analysis

  • PDF Icon

    Report

  • 179 Pages
  • March 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5359449
The Global Atrial Fibrillation Market is estimated to be worth USD 7.8 Billion in 2021 and is expected to reach USD 15.83 Billion by 2026, growing at a CAGR of 15.2%.



Market Dynamics


According to the U.S. CDC, around 12.1 million people in the U.S. are estimated to have atrial fibrillation by 2030. The growing geriatric population, increasing sedentary lifestyle, rising obese population, heavy drinking, and growing disorders leading to heart conditions such as hypertension, atherosclerosis, etc is the major factors raising the prevalence of atrial fibrillation. Furthermore, rising awareness of minimally invasive surgery, healthcare spending, and healthcare tourism is expected to further escalate market growth. However, lack of professional skill and stringent Government regulations of the healthcare sector is anticipated to hinder the market growth.

Rising pharmaceutical innovations coupled with increasing healthcare economies in emerging countries is expected to create new opportunities to the market.

Market Segmentation


The Global Atrial Fibrillation Market is segmented based on Products, Type, and Geography.

  • By Products, the market is classified as surgical devices, non-surgical devices, and drugs. Amongst all, the surgical devices segment is estimated to hold the highest market share during the forecast period.
  • By Type, the market is classified as paroxysmal, persistent, and long-term persistent. Amongst all, the paroxysmal segment is estimated to hold the highest market share during the forecast period.
  • By Geography, North America is projected to lead the market.

Recent Developments


  1. The U.S. FDA has granted Tempus Inc. approval for its ECG Analysis Platform. Developed in collaboration with Geisinger, it helps clinicians identify patients at increased risk of developing atrial fibrillation (AF) or atrial flutter. - 24th March 2021.
  2. Medtronic plc announced the first procedures in the investigational device exemption (IDE) pivotal trial to evaluate the PulseSelect™ Pulsed Field Ablation (PFA) System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation (AF). - 4th March 2021.

Company Profiles


Some of the companies covered in this report are Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Sanofi Aventis, and Abbott Laboratories., etc.

Competitive Quadrant


The report includes the Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?


The report offers a comprehensive evaluation of the Global Atrial Fibrillation Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.

The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel within the industry.

The report includes in-depth market analysis using Porter’s 5 force model and the Ansoff Matrix. The impact of COVID-19 on the market is also featured in the report.

The report also includes the regulatory scenario of the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules & regulations imposed on this sector across various geographies.

The report also contains the competitive analysis using Positioning Quadrants, the analyst's proprietary competitive positioning tool.

Report Highlights


  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Atrial Fibrillation Market

What is the estimated value of the Global Atrial Fibrillation Market?

The Global Atrial Fibrillation Market was estimated to be valued at $7800.0 Million in 2021.

What is the growth rate of the Global Atrial Fibrillation Market?

The growth rate of the Global Atrial Fibrillation Market is 15.2%, with an estimated value of $15830.0 Million by 2026.

What is the forecasted size of the Global Atrial Fibrillation Market?

The Global Atrial Fibrillation Market is estimated to be worth $15830.0 Million by 2026.

Who are the key companies in the Global Atrial Fibrillation Market?

Key companies in the Global Atrial Fibrillation Market include Abbott Laboratories, Johnson & Johnson, MicroPort Scientific Corporation, Boston Scientific Corporation, St. Jude Medica. Inc., Medtronic plc, Biotronik SE & Co. KG, Siemens AG and Biosense Webste. Inc..

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Proprietary Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Increasing Prevalence of Atrial Fibrillation
4.1.2 Rise in Geriatric Population
4.1.3 Increasing Minimal Invasive Procedures
4.2 Restraints
4.2.1 Stringent Government Regulations
4.3 Opportunities
4.3.1 Technological Advancement
4.3.2 Rising Healthcare Expenditure in Emerging Countries
4.4 Challenges
4.4.1 Dearth of Skilled Professionals
4.4.2 Product Recall
4.5 Trends
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Atrial Fibrillation Market, By Product
6.1 Introduction
6.2 Surgical Devices
6.2.1 Maze Surgery
6.2.2 Catheter Ablation
6.2.3 Radiofrequency Catheter Ablation
6.2.3.1 Conventional RF Ablation Catheters
6.2.3.2 Irrigated-tip RF Ablation Catheters
6.2.4 Cryoablation
6.2.5 Microwave Based Catheter Ablation
6.2.6 Laser Based Catheter Ablation
6.2.7 Navigational Advanced Mapping Accessories
6.3 Non-Surgical Devices
6.3.1 Electric Cardioversion
6.3.2 Diagnostic Catheters
6.3.3 Conventional Diagnostic Catheters
6.3.3.1 Fixed Diagnostic Catheters
6.3.3.2 Steerable Diagnostic Catheters
6.3.4 Advanced Diagnostic Catheters
6.3.5 Mapping and Recording Systems
6.3.6 Cardiac Monitors
6.3.7 Access Devices
6.3.8 Left Atrial Appendage and Closure Devices
6.3.9 Intracardiac Echocardiography (ICE) System
6.4 Drugs
6.4.1 Anti-Arrhythmic Drugs
6.4.2 Anti-Coagulant Drugs
7 Global Atrial Fibrillation Market, By Application
7.1 Introduction
7.2 Paroxysmal
7.3 Persistent
7.4 Long-Term Persistent
8 Global Atrial Fibrillation Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 South America
8.3.1 Brazil
8.3.2 Argentina
8.3.3 Chile
8.3.4 Colombia
8.4 Europe
8.4.1 UK
8.4.2 France
8.4.3 Germany
8.4.4 Italy
8.4.5 Spain
8.4.6 Netherlands
8.4.7 Sweden
8.4.8 Russia
8.4.9 Rest of Europe
8.5 Asia-Pacific
8.5.1 China
8.5.2 Japan
8.5.3 India
8.5.4 Indonesia
8.5.5 Malaysia
8.5.6 South Korea
8.5.7 Australia
8.5.8 Sri Lanka
8.5.9 Thailand
8.5.10 Rest of APAC
8.6 Middle-East and Africa
8.6.1 Qatar
8.6.2 Saudi Arabia
8.6.3 South Africa
8.6.4 United Arab Emirates
9 Competitive Landscape
9.1 Competitive Quadrant
9.2 Market Share Analysis
9.3 Strategic Initiatives
9.3.1 M&A and Investments
9.3.2 Partnerships and Collaborations
9.3.3 Product Developments and Improvements
10 Company Profiles
10.1 Abbott Laboratories
10.2 Johnson & Johnson
10.3 MicroPort Scientific Corporation
10.4 Boston Scientific Corporation
10.5 St. Jude Medical, Inc.
10.6 Medtronic plc
10.7 Biotronik SE & Co. KG
10.8 Siemens AG
10.9 AtriCure Inc.
10.10 Biosense Webster, Inc.
10.11 CardioFocus, Inc.
10.12 CathEffects Inc.
10.13 CathRx Ltd.
10.14 EndoPhotonix, Inc.
10.15 Japan Lifeline Co.
10.16 Osypka AG
10.17 Pioneer Medical Devices AG
10.18 GE Healthcare
10.19 TZ Medical, Inc.
10.20 Boehringer Ingelheim GmbH
11 Appendix
11.1 Questionnaire

Companies Mentioned

  • Abbott Laboratories
  • Johnson & Johnson
  • MicroPort Scientific Corporation
  • Boston Scientific Corporation
  • St. Jude Medica. Inc.
  • Medtronic plc
  • Biotronik SE & Co. KG
  • Siemens AG
  • AtriCure Inc.
  • Biosense Webste. Inc.
  • CardioFocu. Inc.
  • CathEffects Inc.
  • CathRx Ltd.
  • EndoPhotoni. Inc.
  • Japan Lifeline Co.
  • Osypka AG
  • Pioneer Medical Devices AG
  • GE Healthcare
  • TZ Medica. Inc.
  • Boehringer Ingelheim GmbH